Tzield
Tzield ingredients
| Active ingredient | Strength |
|---|---|
| Teplizumab | 1 mg/mL |
What Tzield is used for
The FDA lists the approved uses on the official label (below). In the EU, teplizumab is approved as Teizeild for:
Teizeild is indicated to delay the onset of stage 3 type 1 diabetes (T1D) in adult and paediatric patients 8 years of age and older with stage 2 T1D.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Tzield
- Generic name
- Teplizumab-mzwv
- Made by
- Provention Bio, Inc.
- Forms
- Injection
- Given
- Intravenous
- Drug class
- CD3-directed Antibody
- FDA approval
- Biologic licence (BLA) BLA761183
- On the US market since
- 2022
Official information
- Tzield prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Teplizumab-mzwv)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Tzield?
Tzield (Teplizumab-mzwv) is a cancer medicine made by Provention Bio, Inc., approved by the US FDA.
What are the ingredients of Tzield?
Tzield contains Teplizumab (1 mg/mL).
Is Tzield approved in Europe?
The same active substance is approved in the EU as Teizeild.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA